Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Negative Regulation of TNFR1 Signaling Via PKA-Mediated Phosphorylation of TNFR1.

Hapil FZ, Çopuroğlu FE, Ertosun MG, Mert U, Özeş D, Özeş ON.

J Interferon Cytokine Res. 2020 Mar 10. doi: 10.1089/jir.2019.0128. [Epub ahead of print]

PMID:
32159413
2.

The regulation of circadian clock by tumor necrosis factor alpha.

Ertosun MG, Kocak G, Ozes ON.

Cytokine Growth Factor Rev. 2019 Apr;46:10-16. doi: 10.1016/j.cytogfr.2019.04.001. Epub 2019 Apr 2. Review.

PMID:
31000463
3.

Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer.

Gorgisen G, Hapil FZ, Yilmaz O, Cetin Z, Pehlivanoglu S, Ozbudak IH, Erdogan A, Ozes ON.

Genet Mol Biol. 2019 Feb 25;42(1):15-25. doi: 10.1590/1678-4685-gmb-2017-0307. Print 2019 Jan-Mar.

4.

NF-κB-Induced Upregulation of miR-548as-3p Increases Invasion of NSCLC by Targeting PTEN.

Akgun S, Kucuksayan H, Ozes ON, Can O, Alikanoglu AS, Yildiz M, Akca H.

Anticancer Agents Med Chem. 2019;19(8):1058-1068. doi: 10.2174/1871520619666190206165215.

PMID:
30727918
5.

TGF-β-SMAD-miR-520e axis regulates NSCLC metastasis through a TGFBR2-mediated negative-feedback loop.

Kucuksayan H, Akgun S, Ozes ON, Alikanoglu AS, Yildiz M, Dal E, Akca H.

Carcinogenesis. 2019 Jul 4;40(5):695-705. doi: 10.1093/carcin/bgy166.

PMID:
30475986
6.

Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.

Özeş AR, Pulliam N, Ertosun MG, Yılmaz Ö, Tang J, Çopuroğlu E, Matei D, Özeş ON, Nephew KP.

Oncogene. 2018 Jun;37(26):3589-3600. doi: 10.1038/s41388-018-0218-z. Epub 2018 Mar 26.

7.

The role of insulin receptor substrate (IRS) proteins in oncogenic transformation.

Gorgisen G, Gulacar IM, Ozes ON.

Cell Mol Biol (Noisy-le-grand). 2017 Jan 30;63(1):1-5. doi: 10.14715/cmb/2017.63.1.1. Review.

PMID:
28234626
8.

Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells.

Kucuksayan H, Ozes ON, Akca H.

Lung Cancer. 2016 Aug;98:122-129. doi: 10.1016/j.lungcan.2016.05.032. Epub 2016 Jun 3.

PMID:
27393518
9.

NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.

Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, Huang T, Nephew KP.

Oncogene. 2016 Oct 13;35(41):5350-5361. doi: 10.1038/onc.2016.75. Epub 2016 Apr 4.

10.

Differential actıvation and expression of insulin receptor substrate 1 (IRS1) in mononuclear cells of type 2 diabetes patients after insulin stimulation.

Gorgisen G, Balci MK, Celik FC, Gokkaya M, Ozdem S, Ozel D, Ozes ON.

Cell Mol Biol (Noisy-le-grand). 2016 Feb 4;62(2):25-30.

PMID:
26950447
11.

Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).

Gorgisen G, Ozes D, Pehlivanoglu S, Erdogan A, Dertsiz L, Ozbilim G, Ozbudak IH, Savas B, Ozes ON.

Exp Lung Res. 2013 Nov;39(9):387-98. doi: 10.3109/01902148.2013.831960. Epub 2013 Oct 11.

PMID:
24117170
12.

Aplasia ras homologous member I gene and development of glial tumors.

Yakut S, Tuncer M, Berker M, Goksu E, Gurer I, Ozes O, Luleci G, Karauzum S.

Balkan J Med Genet. 2011 Jun;14(1):37-44. doi: 10.2478/v10034-011-0016-1.

13.
14.

Lack of BCL-2 confers interferon-alpha sensitivity to B-cell lymphomas.

Karauzum SB, Yasar D, Dirice E, Imir N, Luleci G, Ozes ON.

Growth Factors. 2007 Apr;25(2):94-100.

PMID:
17852408
15.

Compound heterozygosity for two beta chain variants: the mildly unstable Hb Tyne (codon 5 Pro→Ser) and HbS (codon 6 Glu→Val).

Güzeloğlu Kayışlı Ö, Keser İ, Özeş ON, Canatan D, Yeşilipek A, Lüleci G.

Turk J Haematol. 2005 Mar 5;22(1):37-40.

PMID:
27264516
16.

Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells.

Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK, Donner DB.

Am J Physiol Cell Physiol. 2004 Mar;286(3):C547-55.

17.
18.

Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.

Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB.

J Biol Chem. 2004 Jan 16;279(3):1615-20. Epub 2003 Oct 29.

19.

Suppression of TNF-alpha mediated apoptosis by EGF in TNF-alpha sensitive human cervical carcinoma cell line.

Akca H, Akan SY, Yanikoglu A, Ozes ON.

Growth Factors. 2003 Mar;21(1):31-9.

PMID:
12795334
21.

Hb Antalya [codons 3-5 (Leu-Thr-Pro-->Ser-Asp-Ser)]: a new unstable variant leading to chronic microcytic anemia and high Hb A2.

Keser I, Kayisli OG, Yesilipek A, Ozes ON, Luleci G.

Hemoglobin. 2001 Nov;25(4):369-73.

PMID:
11791869
22.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5. Epub 2001 Apr 3.

23.

Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation.

Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB.

J Biol Chem. 2000 Apr 14;275(15):11216-21.

24.

Stat4 regulates multiple components of IFN-gamma-inducing signaling pathways.

Lawless VA, Zhang S, Ozes ON, Bruns HA, Oldham I, Hoey T, Grusby MJ, Kaplan MH.

J Immunol. 2000 Dec 15;165(12):6803-8.

25.

VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor.

Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB.

J Biol Chem. 2000 Mar 3;275(9):6059-62.

26.

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase.

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB.

Nature. 1999 Sep 2;401(6748):82-5.

PMID:
10485710
27.

Comparison of the in vitro host range of recombinant met-interferon-con1, interferon-alpha 2b, and interferon-beta [corrected].

Hu CJ, Ozes ON, Klein SB, Blatt LM, Taylor MW.

J Interferon Cytokine Res. 1995 Mar;15(3):231-4. Erratum in: J Interferon Cytokine Res 1995 Sep;15(9):828.

PMID:
7584668
29.
32.
33.
34.

A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies.

Reiter Z, Ozés ON, Blatt LM, Sturzl M, Taylor MW.

J Acquir Immune Defic Syndr (1988). 1992;5(5):469-76.

PMID:
1560343
35.
36.

A dual anti-tumor effect of a combination of interferon-alpha and 5-flurouracil or 2-chlorodeoxyadenosine on natural killer (NK) cell mediated cytotoxicity.

Reiter Z, Ozes ON, Tomson S, Blatt LM, Taylor MW.

Adv Exp Med Biol. 1991;309A:69-73. No abstract available.

PMID:
1686352

Supplemental Content

Loading ...
Support Center